Core Insights - Microbix Biosystems Inc. is expanding its platform capabilities to produce a wider range of recombinant antigens, enhancing its market share as a supplier to immunoassay manufacturers [1][3]. Group 1: Company Overview - Microbix has over three decades of experience as a leading producer of purified and inactivated antigens, supplying over 100 international manufacturers of immunoassays [2]. - The company reported sales of native antigens totaling C 0.5 million per year to enhance its internal capabilities in synthetic biology for the production of recombinant antigens [4]. - By the end of 2025, this initiative is expected to broaden the total addressable market by offering a wider range of infectious-disease antigens at various price points [5]. - The recombinant antigens will also serve as ingredients for Microbix's QAPs test-controls, providing immediate internal validation for external customers [5]. Group 3: Market Position and Strategy - Microbix aims to leverage its expertise in recombinant technologies to produce antigens that can offer price advantages over native antigens without compromising assay performance [3]. - The company’s strategic focus on recombinant antigens is anticipated to significantly grow sales in this important segment of its business [3].
Microbix Expanding Addressable Market Share with Test Makers Augmenting its Recombinant Antigen Capabilities for Immunoassay Markets